Helicobacter pylori infection prevents the occurrence of the tolerance phenomenon of histamine H2 receptor antagonists

Alimentary Pharmacology and Therapeutics

Volumn 20, Issue 5, 2004, Pages 559-565

  Fujisawa, T ^a   Adachi, K ^a   Komazawa, Y ^a   Mihara, T ^a   Azumi, T ^a   Katsube, T ^a   Furuta, K ^a   Kazumori, H ^a   Kinoshita, Y ^a  

^a SHIMANE UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CALCITONIN GENE RELATED PEPTIDE; FAMOTIDINE; HISTAMINE H2 RECEPTOR ANTAGONIST; LAFUTIDINE;

ADULT; AMBULATORY MONITORING; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG TOLERANCE; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; LONG TERM CARE; MALE; PEPTIC ULCER; PH; PRIORITY JOURNAL; UREA BREATH TEST;

ACETAMIDES; ADULT; AMBULATORY CARE; CIRCADIAN RHYTHM; CROSS-OVER STUDIES; CROSS-SECTIONAL STUDIES; DRUG TOLERANCE; FAMOTIDINE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HISTAMINE H2 ANTAGONISTS; HUMANS; HYDROGEN-ION CONCENTRATION; MALE; MIDDLE AGED; PIPERIDINES; PYRIDINES;

EID: 4544331926     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2004.02147.x     Document Type: Article

References (36)

1. Jansen JB, Van Oene JC. Standard-dose lansoprazole is more effective than high-dose ranitidine in achieving endoscopic healing and symptom relief in patients with moderately severe reflux oesophagitis. Aliment Pharmacol Ther 1999; 13: 1611-20.
2. Hurlimann S, Abbuhl B, Inauen W, Halter F. Comparison of acid inhibition by either oral high-dose ranitidine or omeprazole. Aliment Pharmacol Ther 1994; 8: 193-201.
3. Komazawa Y, Adachi K, Mihara T, et al. Tolerance to famotidine and ranitidine treatment after 14 days of administration in healthy subjects without Helicobacter pylori infection. J Gastroenterol Hepatol 2003; 18: 678-82.
4. Wilder-Smith C, Halter F, Ernst T, et al. Loss of acid suppression during dosing with H2-receptor antagonists. Aliment Pharmacol Ther 1990; 4(Suppl. 1): 15-27.
5. Smith JT, Gavey C, Nwokolo CU, Pounder RE. Tolerance during 8 days of high-dose H2-blockade: placebo-controlled studies of 24-hour acidity and gastrin. Aliment Pharmacol Ther 1990; 4(Suppl. 1): 47-63.
6. Nwokolo CU, Smith JT, Gavey C, Sawyerr A, Pounder RE. Tolerance during 29 days of conventional dosing with cimetidine, nizatidine, famotidine or ranitidine. Aliment Pharmacol Ther 1990; 4(Suppl. 1): 29-45.
7. Labenz J, Peitz U, Leusing C, et al. Efficacy of primed infusions with high dose ranitidine and omeprazole to maintain high intragastric pH in patients with peptic ulcer bleeding: a prospective randomised controlled study. Gut 1997; 40: 36-41.
8. Netzer P, Gaia C, Sandoz M, et al. Effect of repeated injection and continuous infusion of omeprazole and ranitidine on intragastric pH over 72 hours. Am J Gastroenterol 1999; 94: 351-7.
9. Merki HS, Wilder-Smith CH. Do continuous infusions of omeprazole and ranitidine retain their effect with prolonged dosing? Gastroenterology 1994; 106: 60-4.
10. Sandvik AK, Brenna E, Waldum HL. Review article: the pharmacological inhibition of gastric acid secretion-tolerance and rebound. Aliment Pharmacol Ther 1997; 11: 1013-8.
11. Lachman L, Howden CW. Twenty-four-hour intragastric pH: tolerance within 5 days of continuous ranitidine administration. Am J Gastroenterol 2000; 95: 57-61.
12. Jansen JB, Van Oene JC. Standard-dose lansoprazole is more effective than high-dose ranitidine in achieving endoscopic healing and symptom relief in patients with moderately severe reflux oesophagitis. The Dutch Lansoprazole Study Group. Aliment Pharmacol Ther 1999; 13: 1611-20.
13. Kawano S, Murata H, Tsuji S, et al. Randomized comparative study of omeprazole and famotidine in reflux esophagitis. J Gastroenterol Hepatol 2002; 17: 955-9.
14. Shirota T, Kusano M, Kawamura O, et al. Helicobacter pylori infection correlates with severity of reflux esophagitis: with manometry findings. J Gastroenterol 1999; 34: 553-9.
15. Koike T, Ohara S, Sekine H, et al. Helicobacter pylori infection inhibits reflux esophagitis by inducing atrophic gastritis. Am J Gastroenterol 1999; 94: 3468-72.
16. Loffeld RJ, Werdmuller BF, Kuster JG, et al. Colonization with cagA-positive Helicobacter pylori strains inversely associated with reflux esophagitis and Barrett's esophagus. Digestion 2000; 62: 95-9.
17. Brunner G, Creutzfeldt W. Omeprazole in the long-term management of patients with acid-related diseases resistant to ranitidine. Scand J Gastroenterol 1989; 166(Suppl.): 101-5.
18. Berlin RG, Root JK, Cook TJ. Nocturnal therapy with famotidine for 1 year is effective in preventing relapse of gastric ulcer. Aliment Pharmacol Ther 1991; 5: 161-71.
19. Bianchi Porro G, Lazzaroni M, Barbara L, et al. A controlled study of 20 mg famotidine nocte vs. 150 mg ranitidine nocte for the prevention of duodenal ulcer relapse. Aliment Pharmacol Ther 1991; 5: 181-9.
20. Festen HP. Prevention of duodenal ulcer relapse by long-term treatment with omeprazole. Scand J Gastroenterol 1994; 201(Suppl.): 39-41.
21. Adachi K, Ishihara S, Hashimoto T, et al. Efficacy of sucralfate for Helicobacter pylori eradication triple therapy in comparison with a lansoprazole-based regimen. Aliment Pharmacol Ther 2000; 14: 919-22.
22. Adachi K, Ishihara S, Hashimoto T, et al. Efficacy of ecabet sodium for Helicobacter pylori eradication triple therapy in comparison with a lansoprazole-based regimen. Aliment Pharmacol Ther 2001; 15: 1187-91.
23. Adachi K, Fujishiro H, Mihara T, Komazawa Y, Kinoshita Y. Influence of lansoprazole, famotidine, roxatidine and rebamipide administration on the urea breath test for the diagnosis of Helicobacter pylori infection. J Gastroenterol Hepatol 2003; 18: 168-71.
24. Imai Y, Kobayashi S. A simple method for the quantification of famotidine in human plasma and urine by paired-ion high performance liquid chromatography. Biomed Chromatogr 1992; 6: 222-3.
25. Itoh H, Naito T, Takeyama M. Lafutidine changes levels of somatostatin, calcitonin gene-related peptide, and secretin in human plasma. Biol Pharm Bull 2002; 25: 379-82.
26. Hirschowitz BI, Keeling D, Lewin M, et al. Pharmacological aspects of acid secretion. Dig Dis Sci 1995; 40(Suppl.): 3S-23S.
27. Scott DR, Besancon M, Sachs G, Helander H. Effects of anti-secretory agents on parietal cell structure and H/K-ATPase levels in rabbit gastric mucosa in vivo. Dig Dis Sci 1994; 39: 2118-26.
28. Gillen D, McColl KE. Problems related to acid rebound and tachyphylaxis. Best Pract Res Clin Gastroenterol 2001; 15: 487-95.
29. Graham DY, Malaty HM, Evans DG Jr, Klein PD, Adam E. Epidemiology of Helicobacter pylori in an asymptomatic population in the United States. Effect of age, race, and socioeconomic status. Gastroenterology 1991; 100: 1495-501.
30. Calam J, Gibbons A, Healey ZV, Bliss P, Arebi N. Review article: How does Helicobacter pylori cause mucosal damage? Its effect on acid and gastrin physiology. Gastroenterology 1997; 113(Suppl. 6): S43-9.
31. Kinoshita Y, Kawanami C, Kishi K, Nakata H, Seino Y, Chiba T. Helicobacter pylori independent chronological change in gastric acid secretion in the Japanese. Gut 1997; 41: 452-8.
32. Koike T, Ohara S, Sekine H, et al. Helicobacter pylori infection prevents erosive reflux oesophagitis by decreasing gastric acid secretion. Gut 2001; 49: 330-4.
33. Onodera S, Shibata M, Tanaka M, et al. Gastroprotective activity of FRG-8813, a novel histamine H2-receptor antagonist, in rats. Jpn J Pharmacol 1995; 68: 161-73.
34. Sato H, Kawashima K, Yuki M, et al. Lafutidine, a novel histamine H2-receptor antagonist, increases serum calcitonin gene-related peptide in rats after water immersion-restraint stress. J Lab Clin Med 2003; 141: 102-5.
35. Kawashima K, Ishihara S, Karim Rumi MA, et al. Localization of calcitonin gene-related peptide receptors in rat gastric mucosa. Peptides 2002; 23: 955-66.
36. Saitoh T, Fukushima Y, Otsuka H et al. Lafutidine, a novel histamine H2 receptor antagonist, inhibits daytime acid secretion in both H. pylori infected and non-infected human subjects. J Gastroenterol Hepatol 2002; 17(Suppl.): 828 (Abstract).